(Q38024085)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Marc Weidenbusch

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Christoph Römmele

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Angelika Schröttle

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

3 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

Nephrology Dialysis Transplantation

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

106-111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Assessment of a lupus nephritis cohort over a 30-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Basic and translational concepts of immune-mediated glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

A novel pathogenetic concept-antiviral immunity in lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Effects of rituximab on resistant SLE disease including lung involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

European consensus statement on the terminology used in the management of lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS285

21 January 2018

Identifiers

DOI

10.1093/NDT/GFS285

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22764193%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference